| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/SJ.BJC.6604630 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/sj.bjc.6604630 |
| P932 | PMC publication ID | 2567083 |
| P698 | PubMed publication ID | 18766180 |
| P5875 | ResearchGate publication ID | 23232377 |
| P50 | author | Eleftherios P. Diamandis | Q37383505 |
| P2093 | author name string | L Li | |
| Y Zheng | |||
| I Simon | |||
| D Valik | |||
| T Frgala | |||
| R L Wolfert | |||
| M Nekulova | |||
| K Oikonomopoulou | |||
| M Simickova | |||
| P2860 | cites work | Proteinase-activated receptors, targets for kallikrein signaling | Q24298638 |
| Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance | Q24642804 | ||
| Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker | Q24648238 | ||
| Characterization of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase | Q28209506 | ||
| Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy | Q28276600 | ||
| The emerging roles of human tissue kallikreins in cancer | Q28290701 | ||
| Cancer statistics, 2007 | Q29547293 | ||
| Time-dependent ROC curves for censored survival data and a diagnostic marker | Q30600327 | ||
| Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations | Q30751781 | ||
| Parallel overexpression of seven kallikrein genes in ovarian cancer. | Q30923845 | ||
| Screening for gynecologic cancer | Q33786265 | ||
| Role of tumour markers in monitoring epithelial ovarian cancer | Q33903011 | ||
| Current management of epithelial ovarian carcinoma: a review | Q33959810 | ||
| Proteomic approaches to tumor marker discovery | Q78586166 | ||
| Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor | Q79531733 | ||
| Application of the time-dependent ROC curves for prognostic accuracy with multiple biomarkers | Q82853204 | ||
| Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas | Q34405149 | ||
| Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer | Q34498202 | ||
| B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression | Q34627880 | ||
| Differential gene expression in ovarian carcinoma: identification of potential biomarkers | Q35103006 | ||
| Status of Tumor Markers in Ovarian Cancer Screening | Q35125949 | ||
| Human tissue kallikreins: physiologic roles and applications in cancer. | Q35802061 | ||
| Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer | Q36618953 | ||
| Characterisation of human kallikrein 6/protease M expression in ovarian cancer | Q36626102 | ||
| Mass spectrometry: uncovering the cancer proteome for diagnostics | Q36680064 | ||
| Predicting biomarkers for ovarian cancer using gene-expression microarrays | Q36694599 | ||
| Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer | Q36880603 | ||
| Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. | Q37024500 | ||
| Sequential cleavage of proinsulin by human pancreatic kallikrein and a human pancreatic kininase | Q37338227 | ||
| Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer | Q39796555 | ||
| Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma | Q39806911 | ||
| Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy | Q40180989 | ||
| Kallikreins as markers of disseminated tumour cells in ovarian cancer-- a pilot study | Q40300499 | ||
| Tumor markers in the management of patients with ovarian cancer. | Q40471819 | ||
| Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis | Q40552203 | ||
| Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma | Q43698937 | ||
| Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics | Q43754820 | ||
| Immunohistochemical localization of human kallikreins 6 and 10 in pancreatic islets | Q44455455 | ||
| Overexpression of kallikrein 10 in epithelial ovarian carcinomas | Q44487914 | ||
| The chemopreventive agent alpha-difluoromethylornithine blocks Ki-ras-dependent tumor formation and specific gene expression in Caco-2 cells | Q44825267 | ||
| Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression | Q45267227 | ||
| Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer | Q46988398 | ||
| Distribution of 15 human kallikreins in tissues and biological fluids | Q48134087 | ||
| Combining several screening tests: optimality of the risk score. | Q48621725 | ||
| Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis. | Q50324744 | ||
| National survey of ovarian carcinoma. VI. Critical assessment of current International Federation of Gynecology and Obstetrics staging system. | Q53387574 | ||
| Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer. | Q53890877 | ||
| Activation profiles and regulatory cascades of the human kallikrein-related peptidases. | Q54434829 | ||
| Ovarian cancer specific kallikrein profile in effusions | Q57941661 | ||
| Unfavorable Prognostic Value of Human Kallikrein 7 Quantified by ELISA in Ovarian Cancer Cytosols | Q57942034 | ||
| Human Kallikrein 6 Degrades Extracellular Matrix Proteins and May Enhance the Metastatic Potential of Tumour Cells | Q57942209 | ||
| Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer | Q63446333 | ||
| Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy | Q67922681 | ||
| Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study | Q71528582 | ||
| Enzymatic tumour markers in ovarian cancer: a multiparametric study | Q71619638 | ||
| The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA | Q73141412 | ||
| The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells | Q73202335 | ||
| Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator | Q73407627 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| biomarker | Q864574 | ||
| chemotherapy | Q974135 | ||
| P304 | page(s) | 1103-1113 | |
| P577 | publication date | 2008-09-02 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel | |
| P478 | volume | 99 |
| Q90708882 | A combined score of clinical factors and serum proteins can predict time to recurrence in high grade serous ovarian cancer |
| Q38036543 | A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer. |
| Q93167649 | Age-specific urinary metabolite signatures and functions in patients with major depressive disorder |
| Q47896747 | Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer |
| Q36595049 | Assessment of kallikrein-related peptidase 5 (KLK5) protein expression in tumor tissue of advanced ovarian cancer patients by immunohistochemistry and ELISA: correlation with clinical outcome |
| Q26824446 | B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look |
| Q42104639 | B7-H4 as an independent prognostic indicator of cancer patients: a meta-analysis. |
| Q40523803 | B7-H4 expression in ovarian serous carcinoma: a study of 306 cases |
| Q39508405 | Clinical significance of the B7-H4 coregulatory molecule as a novel prognostic marker in gastric cancer |
| Q37733240 | Combined application of NMR- and GC-MS-based metabonomics yields a superior urinary biomarker panel for bipolar disorder. |
| Q51519421 | Diagnosis value of serum soluble B7-H4 expression in non-small cell lung cancer. |
| Q35196992 | Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions |
| Q33563305 | Electrochemical sensor for multiplex biomarkers detection |
| Q27007065 | Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies |
| Q51601474 | Evaluation of serum and pleural levels of soluble B7-H4 in lung cancer patients with pleural effusion. |
| Q64064460 | Expression of miR-26b in ovarian carcinoma tissues and its correlation with clinicopathology |
| Q36411668 | Expressions of lysophosphatidic acid receptors in the development of human ovarian carcinoma |
| Q38184632 | Function and clinical relevance of kallikrein-related peptidases and other serine proteases in gynecological cancers |
| Q50635567 | GC-MS based metabolomics identification of possible novel biomarkers for schizophrenia in peripheral blood mononuclear cells. |
| Q36226142 | HE4 protein and SMRP: Potential novel biomarkers in ovarian cancer detection |
| Q59813684 | Handheld high-throughput plasmonic biosensor using computational on-chip imaging |
| Q36106333 | Host Protein Biomarkers Identify Active Tuberculosis in HIV Uninfected and Co-infected Individuals |
| Q36125886 | Hydrogel Microwell Arrays Allow the Assessment of Protease-Associated Enhancement of Cancer Cell Aggregation and Survival. |
| Q36508139 | Identification and validation of urinary metabolite biomarkers for major depressive disorder |
| Q37810154 | Industrialized MS-based proteomics in the search for circulating biomarkers |
| Q57177267 | Integrated multiomic predictors for ovarian cancer survival |
| Q30578330 | Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy |
| Q53033550 | MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma. |
| Q64121576 | Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer |
| Q34582595 | OVSCORE - a validated score to identify ovarian cancer patients not suitable for primary surgery |
| Q64060695 | Objective diagnosis of post-stroke depression using NMR-based plasma metabonomics |
| Q38258602 | Potential nanotechnologies and molecular targets in the quest for efficient chemotherapy in ovarian cancer |
| Q29248636 | Prediction of chemo-response in serous ovarian cancer |
| Q38220044 | Predictions for the future of kallikrein-related peptidases in molecular diagnostics |
| Q37690308 | Prognostic value and biological role of the kallikrein-related peptidases in human malignancies |
| Q51662901 | Prognostic value of soluble H7-B4 in pleural effusion associated with lung cancer. |
| Q39913983 | Protein biomarker quantification by mass spectrometry |
| Q91894566 | Quantitative assessment and clinical relevance of kallikrein-related peptidase 5 mRNA expression in advanced high-grade serous ovarian cancer |
| Q39080408 | Secretome and degradome profiling shows that Kallikrein-related peptidases 4, 5, 6, and 7 induce TGFβ-1 signaling in ovarian cancer cells |
| Q33862961 | Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass |
| Q26829844 | The inhibitory role of b7-h4 in antitumor immunity: association with cancer progression and survival |
| Q34076455 | Update on the utility of prognostic biomarkers in ovarian cancer |
| Q36020932 | Upregulation of spondin-2 predicts poor survival of colorectal carcinoma patients |
| Q57155162 | Urinary biomarker panel for diagnosing patients with depression and anxiety disorders |
Search more.